BEAT - BioTelemetry, Inc.
| Previous Close | 42.27 |
| Open | 41.98 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 40.82 - 42.87 |
| 52 Week Range | 38.45 - 80.92 |
| Volume | 236,007 |
| Avg. Volume | 363,984 |
| Market Cap | 1.415B |
| Beta (3Y Monthly) | 1.62 |
| PE Ratio (TTM) | 32.47 |
| EPS (TTM) | 1.29 |
| Earnings Date | Oct 28, 2019 - Nov 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 75.40 |
- Simply Wall St.
Is BioTelemetry, Inc.'s (NASDAQ:BEAT) Capital Allocation Ability Worth Your Time?
Today we are going to look at BioTelemetry, Inc. (NASDAQ:BEAT) to see whether it might be an attractive investment...
- Investor's Business Daily
Why You Should Keep An Eye On These 4 Leading Health Care Stocks
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
- GlobeNewswire
BioTelemetry, Inc. Named to Fortune Magazine’s 100 Fastest-Growing Companies List
BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today it has been ranked 31st on Fortune Magazine’s 100 Fastest-Growing Companies list for 2019. The ranking is based on the combination of revenue growth, earnings growth and the three-year annualized total return. It applies to U.S. publicly traded companies.
- Simply Wall St.
BioTelemetry (NASDAQ:BEAT) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- GlobeNewswire
BioTelemetry, Inc. Names Manish Wadhwa, M.D., F.H.R.S. Chief Medical Officer
BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Manish Wadhwa, M.D., F.H.R.S. (Fellow of the Heart Rhythm Society), has been named Chief Medical Officer. Dr. Wadhwa will lead the company’s clinical strategy and operations, reporting to Joseph H. Capper, President and Chief Executive Officer. Dr. Wadhwa, co-founder of Geneva Health Solutions, joined BioTelemetry in March 2019 as part of the company’s acquisition of Geneva.
- Thomson Reuters StreetEvents
Edited Transcript of BEAT earnings conference call or presentation 30-Jul-19 9:00pm GMT
Q2 2019 BioTelemetry Inc Earnings Call
Motley FoolBioTelemetry Inc (BEAT) Q2 2019 Earnings Call Transcript
BEAT earnings call for the period ending July 30, 2019.
- Zacks
BioTelemetry (BEAT) Q2 Earnings and Revenues Beat Estimates
BioTelemetry (BEAT) delivered earnings and revenue surprises of 17.78% and 0.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioTelemetry, Inc. Reports Second Quarter 2019 Financial Results
Exceeds Expectations Achieves Record Revenue and Adjusted EBITDA MALVERN, Pa., July 30, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology.
- GlobeNewswire
BioTelemetry, Inc. Acquires Sweden-based ADEA Medical AB and Expands International Service Offering
BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that it has acquired ADEA Medical AB, an early-stage Swedish medical technology company that delivers remote health services in the Nordics. The acquisition is aligned with BioTelemetry’s longer-term strategy to increase its international footprint and offer its products and services to physicians and patients in the Nordics and other parts of Europe. BioTelemetry advances health by providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects in a more efficient, accurate and cost-effective manner.
- Zacks
Analysts Estimate BioTelemetry (BEAT) to Report a Decline in Earnings: What to Look Out for
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
BioTelemetry, Inc. to Release Second Quarter 2019 Earnings Results on July 30, 2019
MALVERN, Pa., July 19, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2019 earnings on Tuesday, July 30 at 4:00 PM Eastern Time. The BioTelemetry.
- Zacks
BioTelemetry (BEAT) to Report Q2 Earnings: What's in Store?
BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.
- Simply Wall St.
Does BioTelemetry, Inc.'s (NASDAQ:BEAT) CEO Salary Compare Well With Others?
In 2010 Joe Capper was appointed CEO of BioTelemetry, Inc. (NASDAQ:BEAT). This analysis aims first to contrast CEO...
- Simply Wall St.
With A Return On Equity Of 15%, Has BioTelemetry, Inc.'s (NASDAQ:BEAT) Management Done Well?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- GlobeNewswire
Itamar Medical and BioTel Heart, a Division of BioTelemetry, Expand Collaboration to Offer Itamar’s Total Sleep Solution™ to BioTel Heart Cardiology Customers
Itamar Medical Ltd. (NASDAQ and TASE:ITMR), a company that develops, manufacturers and markets non-invasive diagnostic devices for sleep apnea with a focus on the cardiology market, and BioTel Heart, a division of BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced an expanded collaboration to make Itamar Medical’s Total Sleep Solution available to select BioTel Heart cardiology customers in the United States. The collaboration is designed to respond to the growing demand for home sleep apnea testing among cardiologists, who recognize effective sleep apnea management as a critical strategy for improving health in patients with cardiac disease.
- Zacks
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
BioTelemetry (BEAT) closed the most recent trading day at $47.69, moving +1.6% from the previous trading session.
- Simply Wall St.
Does BioTelemetry, Inc. (NASDAQ:BEAT) Have A High Beta?
If you own shares in BioTelemetry, Inc. (NASDAQ:BEAT) then it's worth thinking about how it contributes to the...
- GlobeNewswire
BioTelemetry President and CEO Joseph H. Capper Named Healthcare CEO of the Year at 26th Annual PACT Enterprise Awards
BioTelemetry (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that Joseph H. Capper, President and CEO, has been awarded the 2019 Healthcare CEO of the Year Award by the Philadelphia Alliance for Capital and Technologies, or PACT. The Healthcare CEO of the Year Award recognizes leaders for their management accomplishments and philosophy, including the communication of a vision and goals as achieved by the company. “Each day we work with our customers and business partners to make a difference in the lives of our patients and communities,” said Joseph H. Capper, President and CEO of BioTelemetry.
- Insider Monkey
Here’s What Hedge Funds Think About BioTelemetry, Inc. (BEAT)
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
- Thomson Reuters StreetEvents
Edited Transcript of BEAT earnings conference call or presentation 25-Apr-19 9:00pm GMT
Q1 2019 BioTelemetry Inc Earnings Call
Motley FoolBioTelemetry Inc (BEAT) Q1 2019 Earnings Call Transcript
BEAT earnings call for the period ending March 31, 2019.
- Benzinga
The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
